Aerie Pharma (AERI) Receives a Buy from Oppenheimer

In a report released today, Francois Brisebois from Oppenheimer maintained a Buy rating on Aerie Pharma (AERI), with a price target of $24.00. The company’s shares closed last Thursday at $11.58, close to its 52-week low of $10.22.

According to TipRanks.com, Brisebois is a 1-star analyst with an average return of -2.3% and a 27.5% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Avadel Pharmaceuticals, Flexion Therapeutics, and Kala Pharmaceuticals.

Aerie Pharma has an analyst consensus of Strong Buy, with a price target consensus of $27.50, which is a 144.1% upside from current levels. In a report issued on September 11, Needham also assigned a Buy rating to the stock with a $26.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $26.26 and a one-year low of $10.22. Currently, Aerie Pharma has an average volume of 710.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.